x
Ariana Pharma
[contact-form-7 404 "Not Found"]

Ariana Pharma
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News & more
    • In The News
    • Case study
    • Publications
      • Publications & Conferences
      • Whitepaper & blog
  • Careers
Logo

Contact Info

  • 58-60 Avenue de la Grande Armée, 75017, Paris, France
  • +33 1 44 37 17 00
  • info@arianapharma.com

Imcyse:Revolutionizing diabetes care with only 41 patients

Overview

New type I diabetes treatment, IMCY-0098, a proinsulin-derived Imotope™ in Phase I developed by Imcyse with first results in only 41 patients

Impact

•  Hypotheses of biomarkers identified by KEM® were implemented and confirmed in phase II with positive results.

•  Positive Phase 1b data triggered Series B Pre-IPO funding of $40m

KEM®’s unique abilities in the unbiased analysis of small datasets with explainable AI enabled Ariana to deliver actionable and powerful insights on IMCY-0098 therapy.

Objectives

•  Identify patient profiles with the highest probability of response to IMCY-0098 therapy.

•  Identify surrogate biomarkers, linked with the therapeutic impact of the treatment, acting as accurate substitute of clinical endpoints.

Method

KEM® systematically associated the treatment and baseline characteristics with the efficacy of the treatment as measured by insulin intake, autoantibodies levels, MMTT (Mixed Meal Tolerance Test), and glycaemia. KEM® enabled the systematic exploration and ranking of all connections between treatment and markers. The explainability of KEM® provided a support to investigators to make a decision for further clinical development plans.

Results

KEM® identified haplotype HLA DR4 as the most responsive subgroup. And CD4/GRB+(CD4, granzyme B+ T-cell) was associated with the dose and identified as a surrogate endpoint.

Read more

Ariana Pharmaceuticals, The AI DRUG Development Company

  • Paris, FRANCE / Cambridge, MA, USA
  • Call Us: +33 144 37 17 00
  • info@arianapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Ariana Pharma © 2024 All Rights Reserved